Cancer NetworkOriginal article
<![CDATA[Divesiran Shows Clinical Responses in Phase 2 Polycythemia Vera Trial]]>
Phase 2positivedivesiranPositive
AI Analysis
Summary
Vera Therapeutics' divesiran met the primary endpoint in the Phase 2 SANRECO trial for polycythemia vera, with 88% of patients achieving response compared to 19% with placebo.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Primary endpoint met with 88% of patients achieving response vs 19% with placebo
Importance:7/10
Sentiment:
0.85
polycythemia veraPhase 2clinical trialprimary endpointSANRECO
Related Companies
Read the original article
Published by Cancer Network on August 11, 2026 3:00 PM